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Abstract: Objective: Rates of AIDS defining event (ADE), serious ADE and death by CD4 and HIV RNA categories be-
fore and after combination antiretroviral therapy (cART) initiation are lacking for high CD4 counts. 
Methods: Event rates were estimated within CD4 cell strata using a Poisson regression model adjusting for sex, exposure 
category, age, and current HIV RNA (<4, 4-4.99, 5 log copies/ml), and including an interaction term between the CD4 
cell count and cART indicator. 
Results : 7317 and 6376 persons contributed to "naïve " and "cART " groups respectively, of whom 3911 contributed to 
both. At the same CD4 level, the risk of ADE was nearly 2 fold higher during naive follow-up compared to cART for 
CD4 <500 cells/mm
3. However, after adjustment for current HIV RNA, the risk of ADE became similar for both groups 
except for CD4 count <200 cells/mm
3 when it is 35% (6-72%) higher for naives. The same results were observed for the 
risk of serious ADE. There was no evidence of a difference in risk of death between naive and cART follow-up at specific 
CD4 categories even after adjustment for HIV RNA. 
Conclusion: Within CD4 cell strata above 200 cells/mm
3, the risk of ADE before ART initiation is higher than it is fol-
lowing cART initiation. 
Keywords: Disease progression, CD4, cART, event rates, prognostic value. 
INTRODUCTION 
  The SMART trial recently closed recruitment after in-
terim analyses demonstrated that persons undergoing a 
treatment interruption once their CD4 cell count reached 
>350 cells/mm
3, restarting once it fell to <250 cells/mm
3, 
experienced significantly worse outcomes compared to those 
randomised to continuous therapy [1]. These CD4 thresholds 
were chosen to provide a safety margin above 200 
cells/mm
3, the level at which current treatment guidelines 
recommend initiation of therapy. These disappointing results 
have rekindled the debate on whether the time is ripe for a 
“when to start” trial to evaluate benefits and risks from initi-
ating antiretroviral therapy (ART) at higher CD4 counts than 
the current 200-350 cells/mm
3 level at which it is considered 
safe to do so [2]. 
  However, there are few published data to inform such a 
trial design [3]. We used data from CASCADE, a large col-
laboration of seroconverter cohorts with CD4 and viral load 
measurements available prior to the initiation of therapy and 
once it is initiated to provide estimates of rates of AIDS, and 
death, at different CD4 categories for persons naïve to ther-
apy as well as those who started combination ART (cART).  
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We also use the derived rates to assess the extent to which 
any differences in risk before and after cART initiation could 
be explained by the effect of cART on HIV RNA level. 
PATIENTS AND METHODS 
  The CASCADE collaboration includes 23 cohorts of per-
sons with well-estimated dates of HIV seroconversion and 
has been described in detail elsewhere [4]. After exclusion of 
patients who started ART in the first 6 months following 
seroconversion, follow-up was categorised as either "naïve", 
including all follow-up while patients were AIDS-free and 
antiretroviral naive individuals at their first CD4 cell count 
after 1 January 1997, and "cART", comprising all follow-up 
of patients once a combination of antiretroviral therapy was 
initiated after 1 January 1997, with at least 3 antiretroviral 
(ARV) drugs, or 2 boosted Protease Inhibitors (PI), or one 
boosted PI and one Non-nucleoside Reverse Transcriptase 
Inhibitor (NNRTI). A given individual could contribute fol-
low up in both categories. Follow-up under non-cART regi-
mens was ignored. For each follow-up category, the baseline 
was defined as the first visit for which an individual's follow-
up qualified for inclusion into that category and until the last 
visit in that category. For "cART", CD4 cell count and HIV 
RNA at baseline were the closest values before cART initia-
tion and up to a maximum of 6 months prior to initiation. 4    The Open AIDS Journal, 2008, Volume 2  Guiguet et al. 
  The following clinical events were studied: (i) new 
AIDS-defining event (ADE), (ii) new serious ADE (all 
AIDS events except for recurrent bacterial pneumonia, oeso-
phageal candidiasis, reccurent herpes simplex, pulmonary 
and extrapulmonary tuberculosis, and unspecified events), 
(iii) death, and two composite end-points: (iv) new ADE or 
death, (v) new serious ADE or death. Patients who died from 
AIDS without a previous AIDS diagnosis were classified as 
ADE progressors. For patients who were not AIDS-free at 
inclusion in the study group, progression was defined by the 
occurrence of the first new clinical event. CD4 cell counts 
were measured with a median periodicity of 98 days, and 91 
days, during the naïve and cART follow-up periods, respec-
tively. CD4 cell counts were modelled using linear interpola-
tion between two measurements. The viral load was deter-
mined with a median frequency of 105 days, and 91 days, 
during the naïve, and cART, follow-up, respectively. CD4 
cell count was categorized in five specific strata (<200, 200-
350, 350-500, 500-650 and 650 cell/mm
3), and HIV RNA 
in three levels (<4, 4-4.99, 5 log copies/ml) [3]. 
  For each group of follow-up, incidence of each outcome 
was estimated within each CD4 cell count stratum. In order 
to test whether, for a given CD4 stratum, the risk of an event 
differs between ART-naïve patients and those who had 
started cART, we included “cART” as an indicator variable 
in a Poisson regression model with an interaction term be-
tween the CD4 cell count and cART. We adjusted for the 
effect of the following potential confounders: sex and expo-
sure category (as a combined variable), and age. A separate 
model further adjusted for current HIV RNA. In assessing 
whether the risk of an event differed between those ART-
naïve and those who had started cART within each stratum 
of CD4 count, an interaction term between the CD4 cell 
count and cART indicator was significant whether the risk of 
ADE was modelled excluding HIV RNA (p=0.002) or in-
cluding it (p=0.03). This interaction term was, therefore, 
included in both models. Statistical analyses were performed 
using SAS software package version 9.1 (SAS Institute, 
Cary, North Carolina, USA). 
RESULTS 
  A total of 7317 patients contributed 12 297 Person-Years 
(PY) of antiretroviral-naïve follow-up with median baseline 
CD4 and HIV RNA of 477 cells/mm
3 and 4.5 log copies/ml 
respectively. After cART initiation, 6376 patients, of whom 
3690 (58%) were pre-treated, contributed 28 864 PY. Of 
these 6376 patients, 3911 (61%) were also followed-up as 
naives, and hence contributed person years to both catego-
ries. Median baseline CD4 and HIV RNA for the patients on 
cART was 310 cells/mm
3 and 4.5 log copies/ml respectively 
(Table 1). The first cART prescription was PI-containing for 
57%, NNRTI-containing for 30%, Nucleoside Reverse Tran-
scriptase Inhibitor (NRTI) only for 10%, and another combi-
nation for 3%. Six months after cART initiation (3 to 9 
months), 73% of previously ART-naive patients experienced 
an increase of >50 cells/mm
3 from baseline and 79% 
Table 1.  Characteristics of Patients Before and After the Initiation of Combination Antiretroviral Therapy (cART) 
 
 ART-Naïve  cART   
Baseline* 
Number of patients  7317 6376 
Age (yrs), median (IQR°)  33 (28-39)  35 (30-41) 
Exposure category/sex (%) 
Sex between men 
Male: injecting drug use 
Female: injecting drug use 
Male: sex between men and women 
Female: sex between men and women 
Other/not known 
 
4074 (56) 
685 (9) 
348 (5) 
698 (9) 
1180 (16) 
332 (5) 
 
3269 (51) 
703 (11) 
396 (6) 
616 (10) 
1059 (17) 
333 (5) 
Time (yrs) from seroconversion to baseline, median (IQR)  1.1 (0.5-3.3)  4.6 (1.8-7.9) 
CD4 (cells/mm3), median (IQR)  477 (340-648)  310 (201-447) 
HIV RNA (log10 copies/ml), median (IQR)  4.5 (3.9-5.1)  4.6 (3.8-5.1) 
Follow-up 
Number of Person-Years  12 297  28 864 
Duration of follow-up (yrs), median (IQR)   0.8 (0.2-2.5)  4.6 (2.1-6.9) 
Number of CD4 measurements, median (IQR)  3 (2-7)  13 (6-23) 
Number of HIV RNA measurements, median (IQR)  3 (1-6)  12 (5-22) 
Cumulative time spent in CD4 strata, years (%) 
 >650 
 500-650 
 350-500 
 200-350 
 <200 
 missing 
 
2981 (24) 
2643 (21) 
3520 (29) 
2040 (17) 
458 (4) 
653 (5) 
 
7357 (25) 
5406 (19) 
6403 (22) 
5004 (17) 
2654 (9) 
2039 (7) 
* 3911 patients contributed to both categories of follow-up. Baseline characteristics are measured at the first visit for "ART-naïve" and at treatment initiation for "cART". 
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achieved HIV RNA <500 copies/ml. The corresponding val-
ues for pre-treated patients were 56% and 59% respectively. 
  Overall, 227 and 146 ADE and serious ADE, and 100 
deaths were observed for the naïve follow-up with a corre-
sponding number of events of 498, 335, and 360 during 
cART follow-up, respectively. Event rates were higher with 
lower CD4 cell counts (Table 2). For ART-naïve individuals, 
ADE rates were markedly higher in those with CD4 count 
below 500 cells/mm
3 compared with higher CD4, varying 
from 0.5 event/100 PY (95% Confidence Interval [CI] 0.2-
0.7) for individuals with CD4 500-650 cells/mm
3 and rising 
to 1.2 (0.8-1.5), 2.6 (1.8-3.2), and 21.8 (17.3-26.2) 
events/100 PY, respectively, at CD4 350-500, 200-350, and 
<200 cells/mm
3. The same trend was observed for serious 
ADE rates. For those who initiated cART, ADE and serious 
ADE rates were generally <1 event/100 PY in CD4 catego-
ries >350 cells/mm
3. The risk of death remained at <1 
event/100 PY for CD4 >200 cells/mm
3. The risk of ADE or 
death overall was 2.5/100PY, and 2.6/100PY, for naïve, and 
cART follow-up respectively, and the respective risk of seri-
ous ADE or death was 1.9/100PY, and 2.1/100PY. 
  Without adjustment for current HIV RNA, the risk of 
ADE was nearly 2 fold higher for ART-naive individuals 
compared to those who started cART for the CD4 count 
categories below 500 cells/mm
3, with risk augmentation of 
58% (95%CI, 4- 140), 78% (95%CI, 24-156), and 85% ( 
95%CI, 46- 135) for CD4 350-500, 200-350, and <200 
cells/mm
3 respectively (Model 1- Table 3). The risk of ADE 
became similar for naives and for those who started cART 
after adjustment for current HIV RNA, except for when the 
CD4 count was below 200 cells/mm
3 when the risk of ADE 
remained significantly higher for naive individuals (Model 
2- Table 3). The data provide evidence that the risk of seri-
ous ADE was significantly higher for naives compared to 
those who started cART, only for CD4 <350/mm
3, before 
adjusting for current HIV RNA (RR and 95%CI= 1.68, 1.07-
2.62 and 2.06, 1.57- 2.71 respectively for CD4 strata 200-
350 and <200 cells/mm
3). After adjustment for current HIV 
RNA, the risk of serious ADE within CD4 categories ap-
peared similar for naives and those who started cART, ex-
cept for when the CD4 dropped below 200/mm
3, as with the 
risk of ADE. In contrast, for fixed CD4 level, there was no 
association between treatment and risk of death irrespective 
of adjustment for HIV RNA. When the analyses were re-
stricted to AIDS-free patients at cART initiation, the same 
results were observed (not shown). Fig. (1) shows the rates 
of ADE, serious ADE, and death estimated using Poisson 
regression. The differences in rates of clinical progression 
between the ART-naïve and cART follow-up, which were 
observed at CD4 counts 200-500 cells/mm
3, disappeared 
once we adjusted for current HIV RNA. This suggests that 
CD4 and HIV RNA had the same prognostic values for na-
ives as for those who started cART, except for CD4 <200 
cells/mm
3 where the independent effect of cART was more 
pronounced. 
DISCUSSION 
  Events rates are extremely high within the lowest CD4 
cell stratum (<200 cells/mm
3), as reported by a number of 
studies [5-8] and fall to 0.5-1 event per 100 PY in those with  
 
Table 2.  Crude Incidence Rates (95% Confidence Intervals) Per 
100 Person-Years (PY), Number with Event and PY of 
Follow-Up in Brackets [], According to Current CD4 
Cell Count (Cells/mm
3) Before and After the Initiation 
of Combination Antiretroviral Therapy (cART) 
 
 CD4  ART-Naïves  cART 
>650  0.7 (0.4-1.0) 
[20/2967] 
0.4 (0.3-0.6) 
[31/7207] 
500-649  0.5 (0.2-0.7) 
[12/2633] 
0.6 (0.4-0.8) 
[30/5258] 
350-499  1.2 (0.8-1.5) 
[41/3494] 
0.7 (0.5-1.0) 
[47/6201] 
200-349  2.6 (1.8-3.2) 
[51/1997] 
1.4 (1.1-1.8) 
[69/4734] 
<200  21.8 (17.3-26.2) 
[92/422] 
11.7 (10.3-13.2) 
[260/2214] 
ADE° 
Missing  1.7 (0.7-2.8) 
[11/625] 
3.1 (2.3-3.8) 
[61/1980] 
>650  0.3 (0.1-0.5) 
[10/2977] 
0.3 (0.2-0.4) 
[19/7266] 
500-649  0.3 (0.1-0.5) 
[7/2640] 
0.3 (0.2-0.5) 
[16/5321] 
350-499  0.6 (0.3-0.8) 
[20/3512] 
0.5 (0.3-0.6) 
[30/6280] 
200-349  1.6 (1.1-2.2) 
[33/2020] 
1.0 (0.7-1.3) 
[47/4831] 
<200  16.1 (12.3-19.9) 
[71/440] 
7.8 (6.7-8.9) 
[185/2366] 
Serious ADE 
Missing  0.8 (0.1-1.5) 
[5/639] 
1.9 (1.3-2.8) 
[38/2001] 
>650  0.5 (0.2-0.8) 
[15/2981] 
0.3 (0.2-0.5) 
[24/7357] 
500-649  0.1 (0.0-0.2) 
[3/2643] 
0.4 (0.2-0.5) 
[19/5406] 
350-499  0.5 (0.3-0.7) 
[18/3520] 
0.6 (0.4-0.8) 
[38/6403] 
200-349  0.5 (0.2-0.8) 
[11/2040] 
0.9 (0.7-1.2) 
[47/5004] 
<200  4.6 (2.6-6.5) 
[21/458] 
5.9 (5.0-6.9) 
[158/2654] 
Death 
Missing  4.9 (3.2-6.6) 
[32/653] 
3.6 (2.8-4.5) 
[74/2039] 
>650  1.1 (0.7-1.5) 
[33/2967] 
0.7 (0.5-0.9) 
[52/7207] 
500-649  0.6 (0.3-0.8) 
[15/2633] 
0.9 (0.6-1.1) 
[46/5258] 
350-499  1.6 (1.2-2.0) 
[56/3494] 
1.3 (1.0-1.6) 
[82/6201] 
200-349  3.1 (2.3-3.8) 
[61/1997] 
2.2 (1.8-2.6) 
[105/4734] 
<200  23.2 (18.6-27.8) 
[98/422] 
14.6 (13.0-16.2) 
[324/2214] 
ADE/death 
Missing  6.2 (4.3-8.2) 
[39/625] 
5.2 (4.2-6.2) 
[104/1980] 
>650  0.8 (0.5-1.1) 
[23/2977] 
0.6 (0.4-0.8) 
[42/7266] 
500-649  0.4 (0.1-0.6) 
[10/2640] 
0.6 (0.4-0.8) 
[32/5321] 
350-499  1.1 (0.7-1.4) 
[38/3512] 
1.0 (0.8-1.3) 
[65/6280] 
200-349  2.1 (1.5-2.8) 
[43/2020] 
1.8 (1.4-2.2) 
[86/4831] 
<200  19.1 (15.0-23.2) 
[84/440] 
11.5 (10.2-12.9) 
[273/2366] 
Serious ADE/death 
Missing  5.5 (3.7-7.3) 
[35/639] 
4.6 (3.7-5.6) 
[93/2001] 
° ADE : AIDS defining event. 
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Table  3.  Effect of Combination Antiretroviral Therapy 
(cART) on Event Rates –AIDS Defining Event 
(ADE), Serious ADE, or Death- Within CD4 Cell 
Strata: Relative Rate (95% Confidence Interval) of 
Clinical Progression for ART-Naïve Follow-Up 
Compared to cART Follow-Up 
 
Model 1  Model 2 
 
CD4 Strata 
(cells /mm
3) 
RR (95%CI)  RR (95%CI) 
ADE 
>650 
500-650 
350-500 
200-350 
<200 
1.60 (0.91-2.81) 
0.82 (0.42-1.60) 
1.58 (1.04-2.40) 
1.78 (1.24-2.56) 
1.85 (1.46-2.35) 
1.08 (0.62-1.92) 
0.55 (0.28-1.09) 
1.04 (0.68-1.60) 
1.15 (0.79-1.66) 
1.35 (1.06-1.72) 
Serious 
ADE 
>650 
500-650 
350-500 
200-350 
<200 
1.37 (0.64-2.95) 
0.91 (0.38-2.22) 
1.21 (0.69-2.14) 
1.68 (1.07-2.62) 
2.06 (1.57-2.71) 
0.93 (0.43-2.03) 
0.62 (0.25-1.53) 
0.80 (0.45-1.42) 
1.07 (0.68-1.69) 
1.48 (1.12-1.95) 
Death 
>650 
500-650 
350-500 
200-350 
<200 
1.78 (0.93-3.41) 
0.38 (0.11-1.30) 
1.02 (0.58-1.79) 
0.67 (0.35-1.28) 
0.80 (0.51-1.26) 
1.79 (0.93-3.43) 
0.37 (0.11-1.25) 
0.95 (0.53-1.68) 
0.61 (0.31-1.19) 
0.79 (0.50-1.25) 
Estimates of event rates using Poisson regression model adjusting on age and exposure 
category/sex (model 1), or age, exposure category/sex and current HIV RNA strata 
(model 2), with an interaction term between cART indicator and CD4 strata. 
 
current CD4 count >350 cells/mm
3. However, the risk of 
ADE was nearly halved after cART initiation compared to 
naïve follow-up when the CD4 count was below 500 
cells/mm
3. If it can be shown through a randomized con-
trolled trial (RCT) that ART is indicated at these higher lev-
els, this has cost and operational implications for HIV treat-
ment and care programmes in developing countries. This is 
not only because of the additional numbers who would be 
eligible for cART, but also because there would likely be no 
need for CD4 testing to evaluate whether an HIV infected 
person is eligible for treatment. 
  It is not surprising that at CD4 >200 cells/mm
3 and after 
adjustment for current HIV RNA, the relative risk of an 
event was similar during cART follow-up and naïve follow-
up because HIV RNA is a surrogate for being on cART. This 
finding is in contrast to that reported from the Frankfurt HIV 
Outpatient Clinic cohort at the beginning of cART era of 
lower event rates for patients at the same CD4 cell count and 
viral load levels receiving a PI-containing regimen compared 
to those not on therapy [9]. The reason for this is not clear, 
but it is of note that much higher event rates were reported 
by that study compared to those observed in our own study, 
both for treated and naïve follow-up. However, after adjust-
ing on HIV RNA, an independent effect of cART was still 
observed in our study with 26% of risk reduction at low CD4 
cell count. 
  We noted relatively high death rates among ART-naïve 
patients with CD4 >350 cells/mm
3. These appear to be due 
to an excess of suicides, accidental deaths and deaths due to 
substance abuse within those CD4 strata as these causes ac-
counted for 53% (8/15) of deaths at CD4 >650 cells/mm
3, 
and for 66% (2/3) and 44% (8/18) of deaths in persons with 
CD4 500-650 and 350-500 cells/mm
3 respectively. 
  Our study has a number of limitations. Firstly, included 
in our cART category are persons who were naïve at the time 
of initiation as well as pre-treated individuals. Although this 
may tend to increase event rates, our observed rates were, in 
fact, lower than those reported by the UK Collaborative HIV 
Cohort Study (CHIC) [3]. It is important to note, however, 
that in CHIC, the ADE and serious ADE rates, in fact, in-
cluded death.  The exclusion of pre-treated individuals did 
not, in any case, have an effect on the evaluation of the 
prognostic value of CD4 and HIV RNA in cART-treated 
compared to naïve follow-up (data not shown). In addition, 
28%, and 16%, of deaths among naive and treated individu-
als, respectively, had no cause recorded preventing us from 
evaluating whether the prognostic value of CD4 and HIV 
RNA is more pronounced for specific causes. Finally, indi-
viduals who happen to be on cART at a given CD4 count 
and HIV RNA levels are different from those who are not. 
Although our analyses adjust for the potential effects of age 
and exposure category as confounders, given the observa-
tional nature of our study, unmeasured confounders remain 
which make it difficult to compare appropriately event rates 
for those on treatment with those who remain off it. In an 
attempt to limit the effect of this bias, we assigned events 
diagnosed in the first week of treatment initiation to the na-
ïve category. Earlier access to therapy, and better immu-
nological and virological responses have been observed 
among homosexual men compared to other groups, particu-
larly to injecting drug users (IDU) [10]. A difference in 
clinical benefit of treatment according to patient characteris-
tics, such the transmission group, has also been reported [8]. 
A number of factors, such as use of health care, lifestyles, 
level of adherence to therapy, as well as the regimen itself, 
are important in determining event rates for those initiating 
cART and could explain differences in event rates between 
studies. These factors will also impact on an evaluation of 
differences in event rates between treated and untreated indi-
viduals who are at similar CD4 and HIV RNA levels. 
CONCLUSIONS 
  Comparing clinical event rates between ART-naives and 
cART-treated follow-up within CD4 cell strata above 200 
cells/mm
3, the risk of AIDS before ART initiation is higher 
than the risk following cART initiation. However, whether 
cART should be initiated at higher CD4 levels than is cur-
rently recommended in the guidelines, can only be evaluated 
through a randomised controlled trial. 
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